GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » FCF Yield %

Genmab AS (STU:GE9) FCF Yield % : 8.62 (As of Mar. 23, 2025)


View and export this data going back to . Start your Free Trial

What is Genmab AS FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Genmab AS's Trailing 12-Month Free Cash Flow is €1,001 Mil, and Market Cap is €11,617 Mil. Therefore, Genmab AS's FCF Yield % for today is 8.62%.

The historical rank and industry rank for Genmab AS's FCF Yield % or its related term are showing as below:

STU:GE9' s FCF Yield % Range Over the Past 10 Years
Min: -0.47   Med: 1.43   Max: 8.62
Current: 8.62


During the past 13 years, the highest FCF Yield % of Genmab AS was 8.62%. The lowest was -0.47%. And the median was 1.43%.

STU:GE9's FCF Yield % is ranked better than
97.14% of 1502 companies
in the Biotechnology industry
Industry Median: -14.29 vs STU:GE9: 8.62

Genmab AS's FCF Margin % for the quarter that ended in Dec. 2024 was 38.98%.


Genmab AS FCF Yield % Historical Data

The historical data trend for Genmab AS's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS FCF Yield % Chart

Genmab AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.82 1.16 1.87 5.00 7.85

Genmab AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.58 4.41 5.35 7.69 10.56

Competitive Comparison of Genmab AS's FCF Yield %

For the Biotechnology subindustry, Genmab AS's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Genmab AS's FCF Yield % falls into.



Genmab AS FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Genmab AS's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=1001.248 / 12752.478
=7.85%

Genmab AS's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=336.699 * 4 / 12752.478
=10.56%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Genmab AS FCF Yield % Related Terms

Thank you for viewing the detailed overview of Genmab AS's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines